Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Forbes

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Clinical Pharmacokinetics|March 7, 2000
Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazolS L Bramer, W P Forbes
DICP : the Annals of Pharmacotherapy|May 1, 1989
Role of milrinone in the management of congestive heart failureD E Hilleman, W P Forbes
Clinical Pharmacokinetics|March 7, 2000
Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokineticsS L Bramer, W P Forbes
Journal of Clinical Pharmacology|April 29, 1998
Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and womenA Suri, W P Forbes, S L Bramer
Clinical Pharmacokinetics|March 7, 2000
Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial diseaseS L Bramer, W P Forbes, S Mallikaarjun
Drug Intelligence & Clinical Pharmacy|December 1, 1987
Comment: Nifedipine in hypertensive emergenciesD E Hilleman, W P Forbes, D Kohll
Clinical Pharmacokinetics|March 7, 2000
Effects of CYP3A inhibition on the metabolism of cilostazolA Suri, W P Forbes, S L Bramer
Clinical Pharmacokinetics|March 7, 2000
Interaction potential and tolerability of the coadministration of cilostazol and aspirinS Mallikaarjun, W P Forbes, S L Bramer
Clinical Pharmacokinetics|March 7, 2000
Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolitesS Mallikaarjun, W P Forbes, S L Bramer
Chest|November 1, 1988
Flecainide-induced cardiogenic shockW P Forbes, T T Hee, S M Mohiuddin, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Clinical Pharmacokinetics|March 7, 2000
Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazolS L Bramer, W P Forbes
DICP : the Annals of Pharmacotherapy|May 1, 1989
Role of milrinone in the management of congestive heart failureD E Hilleman, W P Forbes
Clinical Pharmacokinetics|March 7, 2000
Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokineticsS L Bramer, W P Forbes
Journal of Clinical Pharmacology|April 29, 1998
Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and womenA Suri, W P Forbes, S L Bramer
Clinical Pharmacokinetics|March 7, 2000
Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial diseaseS L Bramer, W P Forbes, S Mallikaarjun
Drug Intelligence & Clinical Pharmacy|December 1, 1987
Comment: Nifedipine in hypertensive emergenciesD E Hilleman, W P Forbes, D Kohll
Clinical Pharmacokinetics|March 7, 2000
Effects of CYP3A inhibition on the metabolism of cilostazolA Suri, W P Forbes, S L Bramer
Clinical Pharmacokinetics|March 7, 2000
Interaction potential and tolerability of the coadministration of cilostazol and aspirinS Mallikaarjun, W P Forbes, S L Bramer
Clinical Pharmacokinetics|March 7, 2000
Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolitesS Mallikaarjun, W P Forbes, S L Bramer
Chest|November 1, 1988
Flecainide-induced cardiogenic shockW P Forbes, T T Hee, S M Mohiuddin, et al.
Pageof 3